Plus Therapeutics, a healthcare company focused on precision diagnostics and radiopharmaceuticals for central nervous system cancers, has appointed Ron Andrews, a veteran with over 35 years in diagnostics, to its Board of Directors. Andrews brings extensive industry experience and connections that will support the scaling and global expansion of CNSide, Plus Therapeutics' proprietary diagnostic test for detecting tumor cells in cerebrospinal fluid. This strategic move aims to enhance patient management for leptomeningeal metastases and drive shareholder value as the company advances its CNS cancer diagnostic and therapeutic pipeline.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Gold and silver prices are under pressure ahead of key U.S. retail sales data that could influence Federal Reserve interest rate decisions. Central banks, led by Poland and China, continue to boost gold reserves, adding 41 tonnes in May, supporting l...
